Trial · NCT02296476
Results by group38
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 38
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Objective Response Rate (ORR) | MK-8628 80 mg | 0 | Participants | ||
| Objective Response Rate (ORR) | MK-8628 120 mg | 0 | Participants | ||
| Objective Response Rate (ORR) | MK-8628 160 mg | 0 | Participants | ||
| Progression-free Survival | MK-8628 80 mg | 0 | Participants | ||
| Progression-free Survival | MK-8628 120 mg | 0 | Participants | ||
| Progression-free Survival | MK-8628 160 mg | 0 | Participants | ||
| Number of Participants Who Experienced at Least One Adverse Event (AE) | MK-8628 80 mg | 6 | Participants | ||
| Number of Participants Who Experienced at Least One Adverse Event (AE) | MK-8628 120 mg | 4 | Participants | ||
| Number of Participants Who Experienced at Least One Adverse Event (AE) | MK-8628 160 mg | 2 | Participants | ||
| Number of Participants Who Experienced at Least One Toxicity Grade 3-5 AE | MK-8628 80 mg | 3 | Participants | ||
| Number of Participants Who Experienced at Least One Toxicity Grade 3-5 AE | MK-8628 120 mg | 1 | Participants | ||
| Number of Participants Who Experienced at Least One Toxicity Grade 3-5 AE | MK-8628 160 mg | 2 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | MK-8628 80 mg | 0 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | MK-8628 120 mg | 0 | Participants | ||
| Number of Participants Who Discontinued Study Treatment Due to an AE | MK-8628 160 mg | 0 | Participants | ||
| Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 | MK-8628 80 mg | 1 | Participants | ||
| Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 | MK-8628 120 mg | 0 | Participants | ||
| Number of Participants Who Experienced a Dose Limiting Toxicity (DLT) During Cycle 1 | MK-8628 160 mg | 2 | Participants | ||
| Observed Maximum Concentration (Cmax) of MK-8628 | MK-8628 80 mg | 1022 | Standard Deviation 377 | μg/Liter | |
| Observed Maximum Concentration (Cmax) of MK-8628 | MK-8628 120 mg | 1138 | Standard Deviation 527 | μg/Liter |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02296476/results